Ardelyx, Inc.
ARDX
NASDAQ·Healthcare·Biotechnology·Mkt cap $933.8M
$3.78
▲ +1.89%
P/E
-16.75
Mkt Cap
$933.8M
52-Wk Range
$3.68–$8.40
52-Week Range
$3.68 - $8.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 42.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-mover advantage in tenapanor with multiple Phase III programs in large patient populations
- Strategic global partnerships reducing commercialization risk and capital requirements
- Differentiated mechanism of action addressing unmet needs in nephrology and gastroenterology
- Experienced management team with track record in biopharmaceutical development and commercialization
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Tenapanor regulatory approval and market launch for IBS-C and hyperphosphatemia indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-31.8% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ARDX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of -$0.07 vs -$0.07 consensus (-7.0% surprise). Revenue of $120.9M vs $121.0M expected (-0.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-7.0%
Revenue trend · last 8Q
—
+238%
+61%
+33%
+12%
+8%
+27%
+24%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$98.2M
$116.1M
$74.1M
$97.7M
$110.3M
$125.2M
$94.5M
$120.9M
Margins · last 8Q
Gross
95.2%
Operating
-10.3%
Profit
-13.8%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 7, 2026
vs Industry
How ARDX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related